Axalbion Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$14.4M
- Investors
-
3
Axalbion General Information
Description
Developer of molecular transducer-based therapies designed to create a safe drug for the treatment of chronic cough. The company's therapies are based on new transducer agonists, identifying two lead candidates, and also offer topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes, as well as by decreasing sensory discomfort, enabling doctors to provide targeted treatment options.
Contact Information
Website
www.axalbion.comCorporate Office
- Medicines Evaluation Unit, The Langley Building
- Southmoor Road, Wythenshawe
- Manchester M23 9QZ
- England, United Kingdom
Corporate Office
- Medicines Evaluation Unit, The Langley Building
- Southmoor Road, Wythenshawe
- Manchester M23 9QZ
- England, United Kingdom
Axalbion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 01-Apr-2024 | $14.4M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC | 07-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 3. Secondary Transaction - Private | 01-May-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC | 06-Jul-2018 | $1.01M | Completed | Clinical Trials - Phase 2 | ||
| 1. Accelerator/Incubator | Completed | Startup |
Axalbion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | 887,900 | $14.61 | $14.61 | 1x | $14.61 | 34.76% | ||
| Ordinary | 219,318 | $9.79 | $9.79 | 2x | $9.79 | 8.59% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Axalbion Patents
Axalbion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2973546-T3 | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for the treatment of chronic cough | Active | 10-Jun-2019 | ||
| AU-2020293622-A1 | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough | Active | 10-Jun-2019 | ||
| AU-2020293622-B2 | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough | Active | 10-Jun-2019 | ||
| AU-2025205040-A1 | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough | Inactive | 10-Jun-2019 | ||
| CA-3143094-A1 | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough | Active | 10-Jun-2019 | A61K31/223 |
Axalbion Signals
Axalbion Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Moulton Goodies | Venture Capital | Minority | ||
| Perscitus | Family Office | Minority | ||
| EPFL Innovation Park | Accelerator/Incubator | Minority |
Axalbion FAQs
-
When was Axalbion founded?
Axalbion was founded in 2016.
-
Where is Axalbion headquartered?
Axalbion is headquartered in Manchester, United Kingdom.
-
What is the size of Axalbion?
Axalbion has 6 total employees.
-
What industry is Axalbion in?
Axalbion’s primary industry is Drug Discovery.
-
Is Axalbion a private or public company?
Axalbion is a Private company.
-
What is the current valuation of Axalbion?
The current valuation of Axalbion is .
-
What is Axalbion’s current revenue?
The current revenue for Axalbion is .
-
How much funding has Axalbion raised over time?
Axalbion has raised $17.7M.
-
Who are Axalbion’s investors?
Moulton Goodies, Perscitus, and EPFL Innovation Park have invested in Axalbion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process